Frontier Capital Management’s UroGen Pharma URGN Stock Holding History

Frontier Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55.5M	Buy	1,508,547 +194,435	+15%	+$5.27M	0.52%	56
2026 Q1	$23.6M	Buy	1,314,112 +532,492	+68%	+$10.7M	0.24%	154
2025 Q4	$18.3M	Buy	+781,620	New	+$17M	0.19%	177

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Frontier Capital Management's URGN Position: Q2 2026 in Review

Frontier Capital Management increased its UroGen Pharma (URGN) stake by 15% in Q2 2026, buying an estimated $5.27M and bringing the position to 1,508,547 shares worth $55.5M. The position accounts for 0.52% of the portfolio, ranked #56.

Frontier Capital Management first reported a position in URGN in Q4 2025 and has held it in 3 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Frontier Capital Management held 1,508,547 shares of UroGen Pharma worth $55.5M as of Q2 2026.
Frontier Capital Management bought 194,435 UroGen Pharma shares in Q2 2026, an estimated $5.27M.
UroGen Pharma made up 0.52% of Frontier Capital Management's portfolio in Q2 2026, its #56 holding.
Frontier Capital Management first reported a position in UroGen Pharma in Q4 2025 and has held it in 3 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.